Araştırma Çıktıları
Permanent URI for this communityhttps://hdl.handle.net/11443/931
Browse
6 results
Search Results
Item High efficacy of onabotulinumtoxinA treatment in patients with comorbid migraine and depression: a meta-analysis(BMC, 2021-01-01) Affatato, Oreste; Moulin, Thiago C.; Pisanu, Claudia; Babasieva, Victoria S.; Russo, Marco; Aydinlar, Elif I.; Torelli, Paola; Chubarev, Vladimir N.; Tarasov, Vadim V.; Schioeth, Helgi B.; Mwinyi, JessicaBackground: Migraine and depression are highly prevalent and partly overlapping disorders that cause strong limitations in daily life. Patients tend to respond poorly to the therapies available for these diseases. OnabotulinumtoxinA has been proven to be an effective treatment for both migraine and depression. While many studies have addressed the effect of onabotulinumtoxinA in migraine or depression separately, a growing body of evidence suggests beneficial effects also for patients comorbid with migraine and depression. The current meta-analysis systematically investigates to what extent onabotulinumtoxinA is efficient in migraineurs with depression. Methods: A systematic literature search was performed based on PubMed, Scopus and Web of Science from the earliest date till October 30th, 2020. Mean, standard deviation (SD) and sample size have been used to evaluate improvement in depressive symptoms and migraine using random- effects empirical Bayes model. Results: Our search retrieved 259 studies, eight of which met the inclusion criteria. OnabotulinumtoxinA injections administered to patients with both chronic migraine and major depressive disorder led to mean reduction of - 8.94 points (CI {[} - 10.04,- 7.84], p < 0.01) in the BDI scale, of - 5.90 points (CI {[} - 9.92,- 1.88], p < 0.01) in the BDI-II scale and of - 6.19 points (CI {[} - 9.52,- 2.86], p < 0.01) in the PHQ-9 scale, when evaluating depressive symptoms. In the case of the migraine-related symptoms, we found mean reductions of - 4.10 (CI {[} - 7.31,- 0.89], p = 0.01) points in the HIT6 scale, - 32.05 (CI {[} - 55.96,- 8.14], p = 0.01) in the MIDAS scale, - 1.7 (CI {[} - 3.27,- 0.13], p = 0.03) points in the VAS scale and of - 6.27 (CI {[} - 8.48,- 4.07], p < 0.01) migraine episodes per month. Comorbid patients showed slightly better improvements in BDI, HIT6 scores and migraine frequency compared to monomorbid patients. The latter group manifested better results in MIDAS and VAS scores. Conclusion: Treatment with onabotulinumtoxinA leads to a significant reduction of disease severity of both chronic migraine and major depressive disorder in patients comorbid with both diseases. Comparative analyses suggest an equivalent strong effect in monomorbid and comorbid patients, with beneficial effects specifically seen for certain migraine features.Item Factors Affecting Adherence to Antiretroviral Treatment among HIV/AIDS Patients in Turkey(BILIMSEL TIP YAYINEVI, 2021-01-01) Nur Karakoc, Hanife; Kaya, Selcuk; Aydin, Merve; Koksal, IftiharIntroduction: Adherence to antiretroviral treatment (ART) is critical for the success of Human Immunodeficiency Virus (HIV) infection treatment. There is no approved consensus that defines adherence. In this study, it was aimed to examine the adherence rate of our patients with high-efficacy ART and to determine the factors affecting treatment adherence. Materials and Methods: Seventy-two patients admitted to the study between January 1, 2018 and July 31, 2018 with the diagnosis of HIV/AIDS who received ART for at least three months and agreed to participate in the study were included in the study. The effect of treatment adherence was investigated by examining the sociodemographic and clink characteristics and laboratory findings, and moods of the patients. Treatment adherence of the patients was evaluated with the Center for Adherence Support Evaluation (CASE) adherence questionnaire and pill counting method. The Hamilton Depression Rating Scale questionnaire was used to investigate the effect of depression severity on treatment adherence in patients. Results: Of the patients, 72.2\% were males and 27.8\% were females. Mean age of the patients was 44.9 +/- 14.8 years. Of the patients, 59.7\% were defined as treatment compatible. Sixty (83.3\%) patients used a single tablet regimen. The most commonly used combination was tenofovir alafenamide-emtricitabine-elvitegravir-cobicistate. Patients' age, disease duration, frequency of follow-up clinic depressive mood, substance use, and HIV positivity in their partners were found effective on treatment adherence. However, sex, marital and educational status, occupation, residential area, transmission route, duration on ART, ART regimen, ART treatment revision, recent CD4+ T lymphocyte count, recent viral load, side effect, additional treatments, antibiotic prophylaxis, smoking habit, alcohol use, comorbidity, co-infection were not statistically associated with treatment adherence. Conclusion: Sufficient awareness should be created by allocating enough time to patients, and patients should be followed up more frequently. Since alcohol and substance use affects treatment adherence, support should be sought from relevant institutions to limit alcohol and substance use in patients. Depressive mood is more common in HIV/AIDS patients compared to the normal population and negatively affects treatment adherence.Item Immersive virtual reality on childbirth experience for women: a randomized controlled trial(BMC, 2022-01-01) Carus, Elif Gizem; Albayrak, Nazli; Bildirici, Halit Mert; Ozmen, Selen GurObjective: To evaluate the effectiveness of immersive virtual reality (VR) on patient satisfaction as a distractive tool and pain relief among laboring women. Methods: This was a randomized, controlled clinical trial with 42 laboring women allocated to VR intervention and control groups. Among women in the VR group, patient satisfaction with the use of VR was assessed by a Virtual Reality Satisfaction Survey, measured by a Visual Analog Scale (VAS) score and evaluated by questioning them about whether they would choose VR in future labor. As a primary outcome, patient satisfaction scores regarding the overall childbirth experience were compared between women in the two groups. A secondary outcome was pain assessed by a visual pain rating scale in the early and active phases of labor in women in both groups. Psychometric information was also collected from participants in each group using the Beck Anxiety Inventory and Beck Depression Inventory. Results: We observed a high level of patient satisfaction with the use of immersive VR during labor. The VAS revealed a mean satisfaction score of 87.7 +/- 12.9 out of a maximum of 100. Twenty out of 21 (95\%) women in the VR group stated that they would like to use VR again in future labor. VR improved pain scores in early labor and contributed positively to the overall childbirth experience. The mean pain score pre-VR was 2.6 +/- 1.2 compared to 2.0 +/- 1.3 post-VR (p < 0.01). Anxiety and depression scores were similar in participants in the intervention and control groups (p = 0.1 03 and p= 0.13, respectively). Conclusion: Immersive VR application during labor was associated with higher patient satisfaction based on our study findings. VR also improved participants' pain scores in early labor before epidural administration. Immersive VR may find a place as an adjunct in labor and delivery units to improve lengthy labor experiences for women. Studies with larger groups of participants are needed to confirm these observations.Item The relation of sexual function to migraine-related disability, depression and anxiety in patients with migraine(BMC, 2014-01-01) Eraslan, Defne; Dikmen, Pinar Yalinay; Aydinlar, Elif Ilgaz; Incesu, CemDepression and anxiety are two phenomena that affect quality of life as well as sexual function. Depression and anxiety levels are reported to be high in migraine sufferers. We aimed to understand whether sexual function in women with migraine was associated to migraine-related disability and frequency of migraine attacks, and whether this relationship was modulated by depressive and anxiety symptoms. As migraine is more commonly seen in females, a total of 50 women with migraine were included. The diagnosis of migraine with or without aura was confirmed by two specialists in Neurology, according to the second edition of International Headache Society (IHS) International Classification of Headache Disorders (ICHD-II) in 2004. Migraine disability assessment scale score, female sexual function index scores, Beck depression inventory score and Beck anxiety inventory scores. Mean MIDAS score was 19.3 +/- 12.8, and mean number of migraine attacks per month were 4.3 +/- 2.7. Mean Female Sexual Function Index score was 20.9 +/- 5.9 and 90\% of patients had sexual dysfunction. Sexual dysfunction was not related to MIDAS score or frequency and severity of attacks. No relationship between sexual function and anxiety was found, whereas severity of depressive symptoms was closely related to sexual function. Depressive symptoms affected all dimensions of sexual function, except for pain. Sexual dysfunction seemed to be very common in our patients with migraine, while not related to migraine related disability, frequency of attacks and migraine severity or anxiety. The most important factor that predicted sexual function was depression, which was also independent of disease severity and migraine related disability. While future larger scale studies are needed to clarify the exact relationship, depressive and sexual problems should be properly addressed in all patients with migraine, regardless of disease severity or disability.Item Association between somatic amplification, anxiety, depression, stress and migraine(BMC, 2013-01-01) Yavuz, Burcu Goksan; Aydinlar, Elif Ilgaz; Dikmen, Pinar Yalinay; Incesu, CemThe aim of this study is to investigate the associations between migraine related disability and somatosensory amplification, depression, anxiety, and stress. Fifty-five migraine patients who applied to the outpatient unit of the Neurology Department of Acibadem University School of Medicine, Maslak Hospital in Istanbul, Turkey, and twenty-eight subjects without migraine were recruited for the study. The participants were asked to complete a sociodemographic form, Migraine Disability Assessment Scale (MIDAS), Depression Anxiety Stress Scale, Somatosensory Amplification Scale (SSAS). Somatosensory amplification scores were significantly higher in the migraineurs than in the control group (29.85+/-6.63 vs 26.07+/-7.1Item Restrained, emotional eating and depression can be a risk factor for metabolic syndrome(ARAN EDICIONES, S L, 2022-01-01) Akillioglu, Tugce; Bas, Murat; Kose, GizemIntroduction: metabolic syndrome (MetS) can have a bidirectional effect on emotional and restrained eating. Objectives: our aims are to find interrelations between MetS and emotional eating, restrained eating, additionally with depression.Methods: cross-sectional study. Participants aged between 18 and 63, and mostly were obese (n = 200). Eating Attitudes Test (EAT-26), Beck Depression Inventory (BDI) and Dutch Eating Behavior Questionnaire (DEBQ) were used to find associations between eating patterns and metabolic syndrome.Results: our study ensured evidences for physiological relations between restrained and emotional eating with MetS. Biochemical parameters showed that restrained eaters were less insulin resistant and participants with MetS had higher emotional eating and lower restrained eating. Besides, restrained eaters had lower triglyceride, homeostasis model assessment-insulin resistance (HOMA-IR), fasting insulin, blood glucose, and higher high-density lipoprotein cholesterol (HDL-C) levels